We have shown that theintramuscular administration of RNase A at doses ranging within 0.5–50 μg/kg leads to theretardation of primary tumor growth by 20–40% with a more pronounced effect at earlystages of tumor development (on the 8th day). The gene discussed is RNASE1; the disease is neoplasm.